Antidepressants, suicide, and the FDA: A loose association

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1739-1742

  Finley, Patrick R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AKATHISIA; ANXIETY; DEPRESSION; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; HYPOMANIA; IMPULSIVENESS; IRRITABILITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

ANTIDEPRESSIVE AGENTS; DRUG LABELING; HUMANS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4644305366     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E247     Document Type: Review

References (26)

1. Food and Drug Administration. Public health advisory, www.fda.gov/cder/ drug/antidepressants/AntidepressantsPHA.htm (accessed 2004 Mar 22).
2. Food and Drug Administration. Psychopharmacologic Drugs Advisory Committee and the Anti-Infective Drugs Advisory Committee. Briefing information. February 2, 2004. www.fda.gov.ohrms/dockets/ac/04/briefing/ 4006b1.htm (accessed 2004 Mar 22).
3. Teicher MH, Glod C, Cole JP. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-10.
4. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003;28:331-7.
5. Healy D, Langmaack C, Savage M. Suicide in the course of the treatment of depression. J Psychopharmacol 1999;13:94-9.
6. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991;303:685-92.
7. Tollefson GD, Fawcett J, Winokur G, Beasley CM Jr, Potvin JH, Faries DE, et al. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiatry 1993;5:209-24.
8. Montgomery SA, Dunner DL, Dunbar G. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995;5:5-13.
9. Waters R. FDA was urged to limit kids' antidepressants. San Francisco Chronicle, April 16, 2004:A1,A19.
10. Mathews AW. FDA revisits issue of antidepressants for youths; new analysis may pressure agency to set limit on use because of suicide risk. Wall Street Journal. August 5, 2004:A1.
11. Sokero TP, Melanin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET. Suicidal ideation and attempts among psychiatric patients with major depressive disorder. J Clin Psychiatry 2003;64:1094-100.
12. Malone KM, Haas GL, Sweeney JA, Mann JJ. Major depression and the risk of attempted suicide. J Affect Disord 1995;34:173-85.
13. Rhodes AE, Links PS. Suicide and suicidal behaviours: implications for mental health services. Can J Psychiatry 1998;43:785-91.
14. Practice guideline for major depressive disorder in adults. Washington, DC: American Psychiatric Association Press, 1993.
15. Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: review of the available evidence. Acta Psychiatr Scand 2001; 104:84-91.
16. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA 2002; 287:203-9.
17. World Health Organization. 2003. www.who.int/mental_health/prevention/ suicide/country_reports/en/ (accessed 2004 Aug 20).
18. Oquendo MA, Kamali M, Ellis SP, Grunebaum MF, Malone KM, Brodsky BS, et al. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry 2002;159:1746-51.
19. Olfson M, Gameroff MJ, Marcus SC, Waslick BD. Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry 2003;60:1236-42.
20. Lapierre YD. Suicidality with selective serotonin reuptake inhibitors: valid claim? J Psychiatry Neurosci 2003;28:340-7.
21. Isacsson G, Bergman U, Rich CL. Epidemiological data suggests antidepressants reduce suicide risk among depressives. J Affect Disord 1996; 41:1-8.
22. Leon AC, Keller MB, Warshaw MG, Meller TI, Solomon DA, Coryell W, et al. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999;156:195-201.
23. American College of Neuropsychopharmacology. Executive summary. Preliminary report of the task force on SSRIs and suicidal behavior. January 21, 2004. www.acnp.org/exec_summary (accessed 2004 Mar 22).
24. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004;350:1489-91.
25. Zito JM, Safer DJ, DosReis S, Gardner JF, Soeken K, Boles M, et al. Rising prevalence of antidepressants among US youths. Pediatrics 2002; 109:721-7.
26. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.